Is Klonopin (Clonazepam) Safe with Ketamine?

If you're on Klonopin (clonazepam) and considering at-home ketamine therapy, the picture is structurally similar to the Xanax page with one important pharmacologic difference: Klonopin has a much longer half-life than Xanax, which changes how we approach minimizing the benzodiazepine load during the ketamine course. The Veraart 2021 systematic review evidence on benzo attenuation of ketamine's antidepressant response applies equally to Klonopin and Xanax (benzos as a class measurably reduce ketamine response), but the operational approach to minimization differs.

What's the same as Xanax

The fundamental Veraart 2021 systematic review finding applies in full. Five separate studies showed consistent attenuation of ketamine's antidepressant response when patients were on concurrent benzodiazepines: significantly longer time to response, significantly shorter duration of response, and significantly higher nonresponse rates at doses above 10 mg diazepam equivalent. The mechanism is GABAergic inhibition dampening the glutamate signaling that ketamine's antidepressant effect depends on. The mechanism is class-wide, so it applies to clonazepam exactly as it does to alprazolam.

The Ford 2015 case report (cited within Veraart 2021) documented the practical consequence: a patient whose ketamine antidepressant response extended from 2-3 days to 10-14 days after their benzodiazepine was withdrawn. Same patient, same ketamine, much longer response off the benzo than on it.

So the verdict for Klonopin is the same as for Xanax: safe in the acute medical sense at therapeutic doses, but the published evidence specifically supports active minimization of the benzodiazepine load during the ketamine course rather than passive continuation.

What's different from Xanax: half-life

Xanax has a half-life of approximately 12 hours. Klonopin's half-life is 30-40 hours, two to three times longer. This pharmacokinetic difference shapes the operational approach to minimization meaningfully.

For Xanax we recommend a session-day hold when the patient can tolerate it: skip the dose on session day, which by session time clears a substantial fraction of the drug from circulation. The half-life math works.

For Klonopin the session-day hold pattern is much less useful. Skipping a single Klonopin dose still leaves the great majority of the drug on board the next day. The reduction in steady-state GABAergic tone from one missed dose is small.

The more useful approach for Klonopin is steady-state dose minimization over time. Working with your prescribing physician to use the lowest functional dose throughout the ketamine course, and considering whether the dose can be reduced as ketamine response stabilizes. This is a longer conversation and a longer timeline than the Xanax session-day hold, but it's the approach that actually works for clonazepam pharmacokinetics.

The dose-threshold note

The Veraart 2021 review identified doses above 10 mg diazepam equivalent per day as a threshold above which ketamine nonresponse becomes more likely. The approximate clonazepam equivalent is 0.5 mg, meaning that 10 mg diazepam roughly equals 0.5 mg clonazepam.

This is worth pausing on because it has counterintuitive implications. A patient on 1 mg Klonopin twice daily (a very common pattern for anxiety or panic disorder) is on 4 mg/day clonazepam, which is approximately 80 mg diazepam equivalent, well above the 10 mg threshold. The patient may consider their dose "modest" but the pharmacologically relevant equivalent is high.

What this means at intake: we don't pretend the threshold doesn't exist. Patients on standard Klonopin regimens (1-4 mg/day) are above the threshold and should expect attenuated ketamine response compared with benzo-free patients. The conversation is honest about this trajectory while still proceeding with ketamine therapy in patients who want to.

What we do at intake

When a patient is on Klonopin, our intake process for ketamine includes:

The dose and timing. Daily total in milligrams; once-daily, twice-daily, or as-needed dosing pattern.

The indication. Anxiety disorders (panic, social, generalized), seizure prophylaxis, restless legs syndrome (off-label), or other.

How long you've been on it. Long-term use (years) shapes how feasible any future tapering conversation is.

Whether you've ever attempted to reduce or come off Klonopin. This shapes our expectations for dose reduction during the ketamine course.

For patients on stable Klonopin regimens we proceed with ketamine onboarding and have an explicit conversation about benzo minimization. For patients on high doses (above 3 mg/day clonazepam) we may recommend a coordinated taper-then-ketamine sequence rather than ketamine on top of an unchanged high-dose regimen, but this is a recommendation, not a precondition.

Klonopin for seizure prophylaxis specifically

If you're on Klonopin for seizure control rather than for anxiety, the conversation shifts in one important way: we do not encourage reducing the dose. Seizure prophylaxis is the primary clinical priority, and ketamine response trajectory is secondary. The dose attenuates the ketamine response, yes, but interrupting seizure control is not an acceptable trade for better ketamine response.

For these patients we coordinate with your prescribing neurologist, proceed with ketamine onboarding while accepting the expected response trajectory, and have an honest conversation at intake about realistic expectations.

Tapering conversations belong with your prescriber

The decision to taper any benzodiazepine belongs entirely to you and your prescribing physician. Klonopin tapering specifically requires a slow, supervised approach because of the long half-life and the seizure risk during withdrawal. We never push it, and we never tie it to ketamine eligibility.

Patients sometimes find that successful ketamine treatment eventually makes a Klonopin taper feasible (as the underlying anxiety or depression improves and breakthrough use becomes less necessary). This is a legitimate clinical trajectory for some patients but not all.

Bottom line

Klonopin is safe to take with at-home ketamine therapy in the acute medical sense, with the same Veraart 2021 evidence-based caveat that applies to Xanax: benzodiazepines measurably attenuate ketamine's antidepressant response and dose minimization improves outcomes. The Klonopin-specific operational note is that the long half-life makes session-day holds less useful and steady-state dose minimization more useful; the approach is a coordinated taper conversation with your prescribing physician over time rather than a per-session dose skip. We do not ask you to stop Klonopin abruptly under any circumstances; withdrawal is medically dangerous including seizure risk.